Just two and a half months after buzzing out of stealth with $300 million and five autoimmune programs from Bristol Myers Squibb, busy Beeline Medicines has flown an extra $126.3 million back to its hive.
Just two and a half months after buzzing out of stealth with $300 million and five autoimmune programs from Bristol Myers Squibb, busy Beeline Medicines has flown an extra $126.3 million back to its hive.
